AbbVie (ABBV) announced that the U.S. FDA approved the use of IMBRUVICA in combination with obinutuzumab for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. The latest FDA approval expands the use of IMBRUVICA, which can already be administered as a single agent or in combination with bendamustine and rituximab (BR) for adult CLL/SLL patients. IMBRUVICA is a once-daily, first-in-class Bruton’s tyrosine kinase inhibitor that is administered orally, and is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech (JNJ).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.